[Circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation. Results of the APAF trial].
Liakishev
A A
AA
D000293:Adolescent; D000328:Adult; D000368:Aged; D000638:Amiodarone / Q000008:administration & dosage / Q000627:therapeutic use; D000789:Angina, Unstable; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000503:physiopathology / Q000628:therapy*; D017115:Catheter Ablation / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D015716:Electrocardiography, Ambulatory; D005260:Female; D005424:Flecainide / Q000008:administration & dosage / Q000627:therapeutic use; D005500:Follow-Up Studies; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011667:Pulmonary Veins / Q000601:surgery*; D013015:Sotalol / Q000008:administration & dosage / Q000627:therapeutic use; D013614:Tachycardia, Paroxysmal / Q000503:physiopathology / Q000628:therapy*; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents; D013015:Sotalol; D005424:Flecainide; D000638:Amiodarone